Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN R.
HUMULIN 70/30 PEN vs HUMULIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro and insulin lispro protamine suspension. Insulin lispro lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production. Insulin lispro protamine provides intermediate-acting basal coverage.
Human insulin is identical to endogenous insulin. It binds to insulin receptors on target cells, activates tyrosine kinase signaling, and promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis while inhibiting gluconeogenesis and glycogenolysis.
Subcutaneous injection, individualized based on metabolic needs and blood glucose monitoring; typical starting dose for type 1 diabetes: 0.5 to 0.6 units/kg/day in divided doses (usually twice daily with 70% intermediate-acting NPH and 30% regular insulin); for type 2 diabetes: 0.2 units/kg/day initially, adjusted per glycemic response.
Subcutaneous: 0.2-0.6 units/kg/day divided into 2-3 doses, individualized. Intravenous: Insulin infusion protocols for hyperglycemia.
None Documented
None Documented
The terminal elimination half-life of insulin in Humulin 70/30 is approximately 1.5 hours for the regular insulin component and 4-6 hours for the NPH component due to protamine suspension, resulting in a prolonged duration of action.
Terminal elimination half-life: 0.5-1 hour (intravenous); prolonged in renal impairment (up to 3-4 hours).
Insulin is primarily eliminated via renal metabolism and excretion; approximately 30-80% is cleared by the kidneys, with the remainder undergoing hepatic metabolism. Biliary/fecal excretion is negligible (<1%).
Primarily renal (>90% as unchanged drug after degradation), with minor biliary/fecal elimination (<10%).
Category C
Category C
Human Insulin
Human Insulin